Research location
Siegen
North Rhine-Westphalia, Germany
Advertisement
Research activity in Siegen
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 25 trials and 29 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Siegen
25 linked trials · page 1 of 1A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityNCT06782490 · 2025-06-05 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10 · 1 site observation
RECRUITING
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple SclerosisNCT06551519 · 2024-10-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520 · 2023-07-25 · 1 site observation
COMPLETED
Implementing Dementia Care Management Into Routine Care in the Region Siegen-WittgensteinNCT05529277 · 2022-09-01 · 4 site observations
UNKNOWN
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · 2020-03-02 · 1 site observation
TERMINATED
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · 2019-07-02 · 2 site observations
ACTIVE_NOT_RECRUITING
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 1 site observation
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaNCT02972658 · 2017-03-15 · 1 site observation
TERMINATED
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)NCT02776072 · 2016-05-01 · 1 site observation
COMPLETED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseNCT02484547 · 2015-09-15 · 1 site observation
TERMINATED
Plegridy Observational ProgramNCT02230969 · 2014-11-12 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseNCT02245737 · 2014-09-30 · 1 site observation
TERMINATED
Dimethyl Fumarate (DMF) Observational StudyNCT02047097 · 2013-11-19 · 1 site observation
COMPLETED
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its OnsetNCT01931566 · 2013-08-01 · 1 site observation
TERMINATED
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's DiseaseNCT00708552 · 2008-07-04 · 1 site observation
COMPLETED
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.NCT00775840 · 2008-01-01 · 1 site observation
COMPLETED
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate AlzheimersNCT00490568 · 2007-08-08 · 1 site observation
TERMINATED
Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.NCT00770653 · 2007-04-01 · 1 site observation
COMPLETED
Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.NCT00770952 · 2006-12-01 · 1 site observation
COMPLETED
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseNCT00348309 · 2006-07-06 · 1 site observation
COMPLETED
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/GlibenclamideNCT00279045 · 2000-01-03 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.